We evaluated the ability of one-month follow-up contrast-enhanced ultrasound (CEUS) with second-generationcontrast agent in monitoring radio frequencyablation (RFA) and transcatheter arterial chemoembolization(TACE) treatments of hepatocellular carcinoma(HCC). One-hundred forty-eight HCCs were studiedusing CEUS: 110 nodules were treated with RFA [41/110RFA were performed using a pretreatment and animmediate postablation evaluation using CEUS (group1); 69/110 using only US guidance (group 2)] and 38nodules treated with TACE. For statistical analysis,McNemar test was used. Overall complete response wasobserved in 107/148 nodules (92/110 treated with RFAand 15/38 with TACE). A better rate of complete responsewas found in group 1 compared to group 2(92.7% vs. 78.3%). In RFA treatment, CEUS showed asensitivity of 83.3% and a specificity of 100% (diagnosticaccuracy of 97%) using MDCT as reference standardwith no statistical difference (p > 0.05). CEUS detectedall cases of incomplete response in HCC treated withTACE using angiography as reference standard (diagnosticaccuracy 100%).We recommend assessing residualintratumoral flow on CEUS during RFA procedure todetermine the necessity of immediate additional treatment.In case of positive CEUS results, HCC treatedwith TACE should be considered still viable.
|Numero di pagine||7|
|Stato di pubblicazione||Published - 2010|
All Science Journal Classification (ASJC) codes